Abstract: Up to 40% of patients with type 1 and type 2 diabetes will develop diabetic nephropathy (DN), resulting in chronic kidney disease and potential organ failure. There is evidence for a heritable genetic susceptibility to DN, but despite intensive research efforts the causative genes remain elusive. Recently, genome-wide association studies have discovered several novel genetic variants associated with DN. The identification of such variants may potentially allow for early identification of at risk patients. Here we review the current understanding of the key molecular mechanisms and genetic architecture of DN, and discuss the merits of employing an integrative approach to incorporate datasets from multiple sources (genetics, transcriptomics, epigenetic, proteomic) in order to fully elucidate the genetic elements contributing to this serious complication of diabetes.

Keywords: diabetes mellitus; diabetic nephropathy; genome-wide association study; single nucleotide polymorphism
1. Background and Introduction

A large proportion of people with diabetes will develop microvascular complications. In addition to microvascular complications, the larger blood vessels become atherosclerotic and the risk for cardiovascular disease is 2–3 times higher compared to people without diabetes [1–3]. Diabetic nephropathy (DN) is the leading cause of end-stage renal disease, present in approximately 25%–40% of patients with long-standing diabetes, affecting kidney function and conferring additional risk of cardiovascular disease and mortality [4–6]. DN is a chronic disorder typically characterized by progressive albuminuria and a decline in renal function. Initial microalbuminuria typically develops to macroalbuminuria over the course of decades [7–9]. Crucially, DN is not clinically detectable until significant kidney damage has developed, highlighting the need to identify early-stage biomarkers.

In contrast to diabetic retinopathy, which increases in incidence as diabetes progresses until almost all patients are affected [10], the incidence of DN peaks at 15–20 years after the onset of diabetes and declines thereafter, with a cumulative incidence of <30% after 25 years of diabetes [11,12]. Not all diabetics with microalbuminuria will progress to macroalbuminuria [13,14], and regression to normoalbuminuria has been reported in several studies [15,16]. Current therapies to treat DN include strict glycemic control and systemic blood pressure interventions targeting the renin-angiotensin system [17–20]. However, optimal blood pressure and glycemic control offer at best partial protection, and high risks of cardiovascular disease, end-stage renal disease and mortality persist [21].

During the development and progression of DN, chronic elevated blood glucose (hyperglycaemia) together with glomerular hypertension leads to renal inflammation, progressive glomerulosclerosis and tubulointerstitial fibrosis resulting in organ failure (Figure 1). High glucose, advanced glycation end-products (AGEs), Angiotensin II, and profibrotic growth factors including transforming growth factor-β (TGF-β) and connective tissue growth factor (CTGF) act on multiple cell types within the kidney to effect mesangial cell matrix expansion, podocyte cell loss, tubule epithelial cell apoptosis and dedifferentiation, macrophage recruitment and fibroblast activation [22–28]. Among the key modulators implicated in the pathogenesis of DN are oxidative stress, protein kinase C, activation of receptor of AGEs (RAGE) and the nuclear factor-κB (NF-κB) transcription factor family (Figure 1) [29–32]. As a result of the diverse functional roles of these resident renal cell populations, it is essential that the variations in gene expression patterns within these cell populations is completely understood in the context of the pathogenesis of DN. Furthermore, epigenetic mechanisms of gene regulation, including DNA methylation, histone modifications and micro-RNA (miRNA) are now being explored in DN [33].

There is evidence for a genetic susceptibility to nephropathy from case-control association and linkage studies, and more recently from genome-wide association (GWA) studies [34,35]. However, as is the case with the majority of complex diseases, identifying precise causal genetic variants contributing to DN has proven difficult. A better understanding of the heritable genetic factors underlying DN and its pathogenesis may lead to the discovery of new biomarkers of disease susceptibility and novel therapeutic strategies. For diseases with complex phenotypes such as DN, integration of multiple data sources promises an improved understanding of the disease pathophysiology. Here we review our present understanding of molecular drivers of DN and key in vitro and animal models of renal fibrosis, we discuss the underlying genetic subcomponent to DN, and finally we explore the merits of integrating data
from multiple sources, including genetics, transcriptomic and epigenomic studies in order to define key targets and pathways worthy of investigation as potential therapeutic targets.

**Figure 1.** The pathophysiology of diabetic nephropathy. As a consequence of prolonged hyperglycaemia, diabetic nephropathy (DN) typically initiates as renal cellular hypertrophy and hyperfiltration, followed by progressive albuminuria and a decline in glomerular filtration rate (GFR). Microalbuminuria (urinary albumin excretion rate of 30–300 mg per day) develops 10–15 years after the onset of diabetes followed by macroalbuminuria (urinary albumin excretion rate of >300 mg per day) 15–25 years after diabetes onset. A combination of hyperglycaemia, inflammation, and hypertension drive the development and progression of DN. Presently, it is unclear why some diabetics are susceptible and others appear protected against the development of DN. Currently unknown causal and protective genetic variants have been suggested as one possible mechanism. At the cellular level, high glucose, Ang II, ROS, and profibrotic cytokines including TGF-β1, VEGF and CTGF have been identified as important modulators driving renal fibrosis. More recently, miRNA-mediated regulation and histone modifications have also been implicated in DN pathogenesis. Mutations in one or more key signaling pathways implicated in DN may act to suppress or drive DN progression.

### 2. High Glucose in Diabetic Nephropathy

Hyperglycaemia is a major stimulus for the development of nephropathy in both type 1 and type 2 diabetes, and the most effective way to minimize the risk of diabetic complications is to maintain optimal glycemic control [36,37]. Several major mechanisms are believed to be responsible for the hyperglycaemia mediated pathological alterations observed in DN, including increased glucose flux through the hexosamine and polyol pathways, oxidative stress and overproduction of AGEs. As proposed by the Brownlee unifying hypothesis, there appears to be a pathogenic link between
hyperglycaemia induced oxidative stress and other hyperglycaemia-dependent mechanisms of vascular damage [22]. Brownlee’s hypothesis proposes that mitochondrial superoxide production limits the flux of glucose through the entire glycolytic pathway, resulting in an increase in all upstream glycolytic intermediates. This increase in concentration of intermediates leads to increased activation of PKC isoforms, increased production of AGEs, and accelerated glucose flux through the polyol and hexosamine pathways.

Renal cells cultured in either physiologic glucose (5 mM) or glucose levels analogous to the diabetic environment (30 mM) are effective in mimicking cellular responses to hyperglycaemia. Studies investigating gene expression in primary human mesangial cells exposed to high glucose have identified a large number of differentially regulated genes [38,39], including modulators of mesangial cell contractility, turnover and matrix metabolism, and genes reported previously to have increased expression in DN (e.g., fibronectin, thrombospondin, caldesmon). Several novel regulators have also been identified including IHG-1 and gremlin, both of which have been the subject of recent functional studies [40–42]. In recent years, miRNA responses in high glucose cultured animal and human renal cells has also been investigated [43,44]. Among those identified, miR-377 is induced by high glucose in both mouse and human mesangial cells, and drives increased fibronectin expression in these cells [45]. Alterations in epigenetic chromatin marks such as histone methylation, acetylation and ubiquitination have also been identified in kidney cells in response to the high glucose environment. Responsive epigenetic marks identified include H3Kme active and repressive marks [46] and H2A/H2B ubiquitination [47].

3. Profibrotic Growth Factors in Diabetic Nephropathy

The growth factor transforming growth factor-β1 (TGF-β1) is recognized as a central cytokine in the development and progression to DN. TGF-β1 is a member of the TGF-β superfamily of proteins, involved in a variety of cell processes including the control of cell growth, proliferation, differentiation and apoptosis [48,49]. TGF-β1 signal transduction is mediated via activation of canonical (SMAD) and non-canonical (p38MAPK, ERK, JNK, PI3K/Akt) pathways [49,50]. TGF-β is secreted by the majority of immune cells and acts as a potent immunoregulatory cytokine [48,50]. There is also evidence that elevated TGF-β levels can promote fibrosis in multiple organs, including the development of DN-associated glomerulosclerosis and tubulointerstitial fibrosis [51,52]. Interventions that reduce TGF-β1 activity have shown therapeutic benefit in renal fibrosis in type 1 and type 2 diabetes [53,54]. However, targeting TGF-β1 for therapeutic intervention is complicated by its dual role in inflammatory and immune processes.

The concentration of TGF-β1 is highly variable and depends on the cellular microenvironment, and measurement of TGF-β1 concentrations within tissues is complicated by the fact that TGF-β1 is stored in the extracellular matrix as a latent form. While plasma and urine TGF-β1 levels have been measured in patients with diabetes and kidney disease, considerable differences are seen between studies [55,56].

TGF-β1 at concentrations of 1–10 ng/mL is routinely used to elicit appropriate fibrotic responses at the cellular level. RNA sequencing transcriptome analysis has identified approximately 2,000 genes differentially regulated in human renal tubule epithelial cells when challenged with high levels of TGF-β1 [57]. The role of tubule epithelial cells in kidney fibrosis is controversial with some studies
suggesting kidney epithelia undergo epithelial-to-mesenchymal transition and migrate towards the interstitium in response to profibrotic cytokines including TGF-β1, thereby contributing towards the scar tissue forming myofibroblast population observed in kidney disease [58]. This theory has been challenged in recent years by lineage tracing studies suggesting that the contribution of renal epithelia to the myofibroblast population is minimal (5%), with resident interstitial and bone marrow-derived fibroblasts the main contributors to the myofibroblast pool [59]. TGF-β1 mRNA containing exosomes released by injured epithelial cells promote fibroblast activation [60], indicating that microparticle-mediated communication may be one possible mechanism through which renal epithelia contribute towards kidney fibrosis.

In addition to gene expression changes, there are several lines of evidence to suggest TGF-β1 induces aberrant alterations in epigenetic marks and miRNA expression. Histone acetylation has been suggested to have an important role in renal epithelial-mesenchymal transition, with treatment of renal epithelial cells with trichostatin A, an inhibitor of the histone deacetylase enzyme, shown to inhibit TGF-β1 induced epithelial-mesenchymal transition [61]. In addition, TGF-β1 treated mesangial cells increase levels of the histone methyltransferase SET7/9, which is associated with the expression of profibrotic genes in these cells [46]. TGF-β1 induces a loss of miR-192 expression in renal epithelial cells, resulting in increased expression of E-Box repressors ZEB1 and ZEB2, and silencing of E-cadherin expression [62–64]. More recently, TGF-β1 has been shown to suppress the let-7 miRNA family in renal epithelial cells resulting in upregulation of let-7 targets TGFβ receptor I, collagens, thrombospondin and the transcription factor HMGA2. Interestingly, treatment of cells with the pro-resolving lipid mediator lipoxin A4 reverses the loss of let-7c and attenuates the TGF-β1 profibrotic signal [65].

While TGF-β1 remains the most studied of the profibrotic cytokines considered as pathogenic mediators of DN, there are a multitude of additional profibrotic growth factors implicated in DN, including vascular endothelial growth factor (VEGF) [66] and connective tissue growth factor (CTGF) [67]. In human mesangial cells, both high glucose and TGF-β1 induce CTGF expression, mediated via TGF-β1-dependent and protein kinase C (PKC)-dependent pathways [67]. CTGF enhances expression of multiple extracellular matrix proteins observed in DN including collagens I and IV and fibronectin [39]. In an animal model of type 1 diabetes (STZ rat), CTGF renal expression is elevated at the time of mesangial expansion and proteinuria [39]. More recently, a study investigating the signaling interplay between CTGF and TGF-β1 in human mesangial cells identified upregulation of miR-302d and targeting of TGFβ receptor II in response to CTGF [68].

4. Animal Models of Diabetic Nephropathy

In 2001, the Animal Models of Diabetic Complications Consortium (AMDCC) was set up by the National Institutes of Health to develop murine models of diabetic micro and macrovascular complications that completely replicate the human diseases [69]. Currently, there is a lack of reliable animal models that mimic nephropathy in human type 1 or type 2 diabetes, and the debate as to what exactly is the best animal model is somewhat controversial. Chemical agents such as streptozotocin (STZ) can selectively damage the insulin-producing beta-cells in the pancreas resulting in hyperglycaemia and are long recognized as important tools for developing animal models of diabetic complications [70–72]. However while this model induces kidney hypertrophy and mesangial
expansion, it does not progress to more advanced renal disease seen in humans which is characterized by a loss of glomerular filtration, overt proteinuria, advanced structural lesions and tubulointerstitial fibrosis [70,71]. Mouse models of endothelial dysfunction, with a targeted mutation in the Nos3 gene encoding endothelial nitric oxide synthase are recognized as one of the more robust models of advanced renal disease in diabetes; these animals exhibit a decline in glomerular filtration and tubulointerstitial fibrosis [71]. Recently developed mouse models with a leptin receptor mutation develop type 2 diabetes, hypertension, obesity and on the db/db or BTBR ob/ob background develop proteinuria, reduced glomerular filtration, mesangial matrix expansion and podocyte loss [73], thereby recapitulating nephropathy in type 2 diabetes. Finally, the unilateral ureteral obstruction (UUO) rat model, generated through ligation of the ureter, results in marked renal hemodynamic changes, followed by tubular injury, cell death and interstitial macrophage infiltration, and is considered an important model for tubulointerstitial fibrosis [74–77].

While no single-animal model exists that recapitulates all of the pathological features of established human nephropathy in type 1 and type 2 diabetes, these animal models have provided valuable information regarding many aspects of DN including pathophysiology and implicated genes. Microarray analysis of glomerular gene expression profiles in diabetic rats has identified numerous signaling networks implicated in human DN, including extracellular matrix interacting genes, renin-angiotensin, TGF-β1, Smad and NF-κB pathways [78–81].

5. Human Studies in Diabetic Nephropathy

5.1. Gene Expression Studies in DN

Genome-wide transcriptome analysis of human tissues using expression arrays or next-generation sequencing is a common strategy used to gain insight into disease pathogenesis and identification of biomarkers. Comprehensive studies analyzing gene expression in renal biopsies from DN patients are somewhat limited due to the invasive nature and risks associated with biopsy. In recent years, several gene expression studies have been performed on DN patient renal biopsies, leading to the identification of potential causal pathways. The first such study performed by the European Renal cDNA Bank focused on transcriptome analysis of tubulointerstitial tissue from DN patients of Caucasian backgrounds. It identified components of the NF-κB regulated transcriptome to be upregulated in DN [32]. More recently, a comprehensive microarray study of DN kidney biopsies from ethnically diverse patients microdissected into glomerular and tubulointerstitial compartments identified both common and distinct expression networks and pathways implicated in disease, including the complement cascade, RhoA, Cdc42, integrin, integrin-linked kinase, and vascular endothelial growth factor signaling in DN glomeruli [82].

An important consideration when using in vitro and in vivo model systems is how accurate these models are in mimicking human DN. An example of where in vitro models can inform human disease is seen in a recent study of human kidney epithelial cells exposed to albumin identifying 231 differentially expressed genes, which were subsequently used as a classifier set to distinguish control versus IgA nephropathy biopsies [83]. A similar strategy was utilized to correlate whole-transcriptome expression data from TGF-β1 stimulated kidney epithelial cells with expression data from renal
biopsies of patients with DN versus healthy donor controls. This study identified a cohort of 179 co-regulated transcripts [57]. Pathway analysis of the genes regulated by TGF-β1 in this model system identified an enrichment of NF-κB pathway genes, which closely mimics what is observed in human DN biopsies.

5.2. Epigenetic Studies in DN

Emerging evidence suggests that epigenetic mechanisms play a role in the development of renal diseases such as DN. Clinical and experimental studies demonstrate the occurrence of a hyperglycemic memory due to previous exposure to high glucose levels, resulting in persistently increased risk for DN [84]. Proposed epigenetic mechanisms include glucose-induced effects on histone modifications leading to modulation of vascular gene expression, which persists despite a return to normoglycemia [85]. Monocytes from diabetic patients also exhibit histone modifications including changes H3K9me2 and H3K4me2, which are associated with immune and inflammatory pathways [86]. Alterations in DNA methylation profiles has also been reported, with a genome-wide DNA methylation analysis of type 1 diabetes patients with or without nephropathy identifying CpG sites where the degree of methylation correlated with time to development of DN [87]. Due to the cell-specific nature of epigenetic marks several issues arise when using patient samples and cell model systems. Firstly, while the identification of predictive epigenetic marks in DN patient blood offer excellent high-throughput and non-invasive screening potential, the functional relevance of these marks to the distant kidney, composed of many different cell types each with potentially distinct epigenetic profiles, is unclear. Secondly, the validity of cell lines in DNA methylation studies in DN has been called into question. A comparison of DNA methylation profiles in peripheral blood leukocytes versus lymphoblastoid cell lines generated from the same DN patients identified differential methylation in 8% of the promoter CpG islands assessed, raising doubts over the utility of EBV-transformed cell lines [88]. Finally, the utility of short-term stimulations routinely used in in vitro models of DN to investigate epigenetic marks is also questionable. For example, while there is abundant evidence of global gene expression changes in kidney cells cultured in the presence of profibrotic growth factors within 24 h, there is also evidence that DNA methylation changes may not become apparent at these genes for several days [89]. As a result, extended time-course experiments will be essential when investigating epigenetic marks in cell models of DN.

miRNA profiling in a number of diseases, including diabetic complications has also been performed. Considering the cell-specific nature of miRNA expression, the vast majority of studies implicating miRNA signaling cascades in the pathogenesis of DN have focused on individual resident renal cell populations (epithelial, mesangial, podocyte) using the in vitro and animal model systems described in this review. Among the numerous miRs implicated in diabetic kidney disease are miR-192, miR-200, let-7c, miR-21, miR-29 and miR-37 [45,64,90–92]. miR-192 is perhaps the most studied micro-RNA in human kidney disease, and the precise role of this miR remains unclear due to conflicting reports. While some studies have reported increased renal miR-192 expression in diabetic mice and also in mouse and rat kidney cells in response to TGF-β1 [63,93], other studies have reported the opposite trend [64]. The observed differences are likely to be due to different models being used, cell-specific responses, and cell culture conditions. Analysis of miRNA expression levels in renal...
Genes 2013, 4 603

biopsies reported a loss of miR-192 which correlated with severity of kidney disease in DN patients [43], and several studies have also reported loss of miR-192 in human renal epithelial cells stimulated with TGF-β1 [43,65]. Despite the difficulties associated with interpreting these results, it is clear that miR-192 likely plays an important role in kidney disease. More recently, several studies have explored the potential use of urinary miRNA expression levels in DN patients as biomarkers of disease progression [94,95]. Presently, there are several limitations to miRNA therapeutics in DN and other human diseases including the fact that miRNAs may target hundreds of transcripts in addition to a desired target transcript, and precise delivery of these miRNAs to specific sites of kidney injury will be required. Interestingly, a miR-34 mimic which targets known oncogenes has recently entered a phase 1 trial in patients with liver cancer [96].

6. Genetic Architecture of Diabetic Nephropathy

Gene Discovery in Diabetic Nephropathy

Early evidence for heritability of DN came from family-based studies reporting clustering of nephropathy in sibling pairs with type 1 and type 2 diabetes [97–99]. Likewise, a parental history of hypertension or cardiovascular disease is predictive of DN [100,101]. Despite the fact that linkage studies have identified several chromosomal regions linked with nephropathy in type 1 and type 2 diabetes [102–110], no linkage peaks have been robustly reproduced across multiple studies. Candidate genes investigated for association studies in DN have primarily been selected based on results from these genome-wide linkage scans and putative biological role in pathways implicated in the pathogenesis of DN. Thus, candidate genes investigated for association with DN include: profibrotic growth factors (CTGF, TGFβ1, TGF-β receptors 2 and 3, VEGF) [111–115]; BMPs and antagonists (BMP-2,4,7, gremlin) [40,116]; inflammatory molecules (ICAM1, MCP1, RAGE) [117–119]; and dyslipidemia-related genes [120].

Angiotensin-converting enzyme (ACE) inhibitors are routinely used antihypertensive agents in the treatment of DN, and the ACE insertion/deletion (I/D) polymorphism is perhaps the most well-studied candidate gene in DN [121–126]. Despite conflicting results reported for this polymorphism, a meta-analysis of 47 studies showed that the ‘II genotype’ has a potentially protective effect. It confers a markedly lower risk of developing DN than seen in carriers of the “D allele” [127]. SNPs within the angiotensinogen (AGT) and angiotensin II receptor, type 1 (AT1) genes are also associated with a higher risk of developing nephropathy [128]. However, as is the case with many complex disease genetic studies, where candidate gene associations have been reported in DN, consistent replication across multiple studies has been limited, suggesting that large-scale genome-wide efforts will be required to identify putative candidate genes.

Genome-wide association (GWA) studies have identified more than 100 genetic variants associated with type 1 and type 2 diabetes [129–134], with successful GWA studies also reported for non-diabetic kidney diseases such as IgA, ANCA-associated and idiopathic membranous nephropathy [135–139]. However, GWA studies in DN have so far proven less fruitful, with robust replication of many initial associations not forthcoming. Reasons for a lack of corroboration include a combination of effects due to small sample sizes, modest gene effect sizes, population stratification and lack of consistency with
respect to patient recruitment criteria, phenotype definition and statistical analysis. It is now apparent that in order to fully elucidate the genetic elements contributing to nephropathy in diabetes, collaborative efforts merging sample collections for analysis in GWA studies are required.

In 2009, the U.S. Genetics of Kidneys in Diabetes (GoKinD) GWA study analyzed SNPs in 820 DN case subjects and 885 control subjects with type 1 diabetes but no evidence of DN [34]. Although no risk variant achieved genome-wide significance, the primary association analysis identified 11 SNPs representing four distinct chromosomal regions. Among the associated variants was a SNP located in the promoter of the FRMD3 gene. FRMD3 (FERM domain containing 3) belongs to the family of band 4.1 proteins, encoding adaptors of plasma membrane receptors to the actin cytoskeleton. Multiple SNPs in the FRMD3 gene have been reported to be associated with nephropathy in both type 1 and type 2 diabetes in European, African and Asian populations [140]. Interestingly, a recent study has defined a putative functional role for the promoter SNP rs1888747 [140,141]. Here, the FRMD3 transcript was shown to be co-expressed with BMP signaling pathway components in renal biopsies of DN patients. In the same study, bioinformatic analysis of the FRMD3 and BMP family promoter sequences identified shared transcription factor binding sites, suggesting co-regulation with the BMP family. A comprehensive meta-analysis for genetic variants associated with DN, selecting only variants where associations were independently reproduced, identified 24 loci of interest including ACE and FRMD3 polymorphisms [142]. In 2012 the Genetic of Nephropathy—an International Effort (GENIE) consortium completed a large meta-analysis and GWA study, consisting of 6,366 participants of European ancestry with type 1 diabetes, with and without nephropathy [35]. Associated variants were identified in several novel candidate genes: AFF3, ERBB4, 15q26, and functional data implicated AFF3 in TGF-β1 mediated renal tubule fibrosis. Variants in AFF3 have been reported in a GWA study for type 1 diabetes [129,143], and ERBB4 has also been shown to have a potentially important biological role in kidney tubule integrity [144,145]. More recently, this consortium has also identified a sex-specific genetic variant on chromosome 2 strongly associated with end-stage renal disease in female patients with type 1 diabetes [146]. While independent replication of this signal will be required, this robustly associated genetic variant may explain how some diabetic women lose their protection against end-stage renal disease.

Despite the promising replication observed in a previous meta-analysis [142], this consortium was unable to replicate most of the previously reported genetic associations for nephropathy in type 1 diabetes [147]. Importantly, additional consortia have now been established to perform GWA studies in DN, including SUMMIT [148]. Future directions to identify genetic variants associated with diabetic kidney disease will require replication of GWAS signals to determine whether these are indeed ‘true’ DN-associated variants, merging of these datasets to increase statistical power, investigation of rare low-frequency variants not captured by standard GWA study approaches (exome chips), and use of extreme phenotype cohorts in association studies.

7. Integrating Multi-Layered Datasets in Diabetic Nephropathy

While association and linkage studies provide an enormous amount of information, incorporation of multiple sources of evidence is necessary to decipher biological processes linked to DN. It is through integration of multiple layers of evidence (genome-wide association studies, transcriptomics, epigenomics,
proteomics and metabolomics) that promising candidate genes and pathways will be discovered. There are now several web resources available which collate published renal disease datasets. Nephromine [149], a resource of renal gene expression profiles provides current information on existing datasets related to DN and other kidney disease phenotypes. Others include: the Kidney and Urine Pathway Knowledge Base [150,151] which contains experimental data (mRNA, proteins and miRNA) coming from published articles related to kidney physiology and pathology; the Human Kidney and Urine Proteome Project, an initiative project of the Human Proteome Organization to analyze human kidney and urine by proteomics [152]; and EuReGene, the European Renal Genome Project [153], an atlas of gene expression in the developing and adult mouse kidney.

A recent study merged publicly available omics data specific for DN along with DN-associated data retrieved from scientific literature, and subsequently mapped these data onto a protein interaction network [154]. These data identified the renin-angiotensin, complement and coagulation cascade, and PPAR pathways as primary targets worthy of further investigation in DN. In recent years, several web-applicable tools have been developed to facilitate the merging of multiple omics datasets to identify candidate genes, including ENDEAVOUR and CANDID [155,156]. More recently, MetaRanker has been developed to identify susceptibility genes based on meta-analysis of heterogeneous data from GWA studies, protein-protein interaction screens, disease similarity, linkage studies, and gene expression experiments which is used to prioritize candidate genes [157,158]. Approaches such as these that incorporate multiple layers of evidence will most likely identify highly relevant DN-associated genes (Figure 2).

**8. Discussion and Conclusions**

Diabetes and associated complications represent a significant health and economic burden, and given the emerging epidemics of obesity and diabetes in children and adolescents these increases in prevalence are expected to continue. Diagnosis of DN is typically made using clinical criteria (albuminuria, serum creatinine) rather than invasive renal biopsy. However, DN is not clinically detectable until significant kidney damage has developed, highlighting the need to identify early-stage biomarkers.

Despite the large body of evidence for a heritable genetic component to nephropathy in type 1 and type 2 diabetes, the underlying genetic mechanisms remain poorly understood, with no robust DN candidate genes yet identified. While the majority of candidate gene studies in DN have tended to focus on strong biological candidates, it is interesting to note that as data emerges from GWA studies the majority of signals reside in novel genes, often with little known on their precise biological role. This would suggest that novel risk factors and pathways may play an important role in the progression and development of DN. It is likely that mutations in multiple genes distributed across the genome, each with a modest effect size, may be causal or protective factors in the development and progression of DN. As is the case with many complex diseases, robust replication of DN-associated gene variants across multiple populations has been limited. Therefore, an essential step towards identifying variants associated with nephropathy in diabetes will involve: merging patient cohorts across multiple populations to increase sample size to detect gene associations of modest effect; investigating rare variants which are not captured by current GWA studies; and defining clear disease phenotype criteria.
Figure 2. Unravelling the genetic and molecular mechanisms that cause DN development and progression. The clinical course of DN is relatively well defined. Diagnosis of DN is complicated by the fact that: (a) patients with microalbuminuria may undergo spontaneous regression to normoalbuminuria; and (b) glomerular filtration rate (GFR) and albuminuria may progress independently of each other, i.e., patients may have micro- or macro-albuminuria even though their GFR is normal. Macroalbuminuria is usually associated with reduced GFR. Large scale genome-wide association (GWA) studies in DN are now feasible—future direction will require merging of patient cohorts, use of alternative phenotype definitions to the standard albumin excretion rate definition (e.g., estimated GFR, serum creatinine), analysis of extreme phenotype cohorts, and rare-variant GWA studies. To prioritize candidate genes from GWA studies in DN, these datasets will be integrated with whole-genome expression, proteomic, micro-RNA and epigenomic markers datasets using newly developed integrative tools to merge such datasets. As prioritized candidate genes are identified, functional analysis of these genes will be performed in established cell and animal models of DN.

It is now clear that there is a need for improved or alternative phenotype definitions to the standard trait for genetic studies of DN—albuminuria. DN disease progression is variable; some patients progress relatively fast, whereas others do not, which could indicate a potentially heterogeneous disease. We now know that proteinuria is more variable in DN than initially thought, with regression from microalbuminuria to normoalbuminuria frequently observed during the early stages of DN [14], and studies reporting advanced diabetic kidney disease in the absence of proteinuria [159]. More
recently, renal decline as measured by loss of eGFR has been reported in type 1 diabetics with normoalbuminuria, suggesting that this early renal decline precedes and drives progression towards microalbuminuria and macroalbuminuria [160]. As seen in a recently completed large-scale GWA study in type 1 DN, no single locus reached genome-wide significance when the accepted phenotype definitions were used to define DN cases (macroalbuminuria or end-stage renal disease) and diabetic controls with normal albumin excretion [35]. In the same study, when the DN case definition was modified to include only diabetic end-stage renal disease patients, i.e., the most extreme cases, genome-wide significant signals were identified. Independent replication and fine-mapping of these loci will be essential to determine whether these are indeed ‘true’ end-stage renal disease signals. As a result, future GWAS in DN will consider additional phenotype definitions focusing on quantitative traits including serum creatinine and glomerular filtration rate.

Due to significant technological advances in recent years the cost of performing whole-transcriptome profiling has become more feasible, allowing for further investigation into the mechanisms driving this serious complication of diabetes. Presently, a large body of research in DN is focused on in vitro and animal models of DN. However, the lack of animal models that mimic human DN is a major obstacle to be overcome. While these model systems have proven to be invaluable tools in aiding our understanding of the pathophysiology of DN, there is a need for a more comprehensive analysis of human material (biopsy, urine, blood) from DN patients. Transcriptomic profiling via RNA sequencing, epigenomic profiling, and proteomic analysis of primary resident cell types and kidney compartments will be required to comprehensively map responsive markers during the development and progression of DN. As the wealth of data generated from these high-throughput techniques are integrated with GWA study data, and incorporated with additional layers of evidence, emerging computational tools will be utilized to define enriched gene pathways and networks.

Acknowledgments

Work in the authors’ laboratory is supported by Science Foundation Ireland Investigator Award (SFI 06/IN.1/B114) and The GENIE Consortium is supported by SFI US Ireland R&D Award (SFI/08/US/B1517), the Northern Ireland Research and Development Office, and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (R010-DK081923).

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Laing, S.P.; Swerdlow, A.J.; Slater, S.D.; Burden, A.C.; Morris, A.; Waugh, N.R.; Gatling, W.; Bingley, P.J.; Patterson, C.C. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. *Diabetologia* **2003**, *46*, 760–765.
2. Groop, P.H.; Thomas, M.C.; Moran, J.L.; Waden, J.; Thorn, L.M.; Makinen, V.P.; Rosengard-Barlund, M.; Saraheimo, M.; Hietala, K.; Heikkila, O.; et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. *Diabetes* 2009, 58, 1651–1658.

3. Haffner, S.M.; Lehto, S.; Ronnemaa, T.; Pyorala, K.; Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N. Engl. J. Med.* 1998, 339, 229–234.

4. Byrne, C.; Ford, D.; Gilg, J.; Ansell, D.; Feehally, J. UK Renal Registry 12th Annual Report (December 2009): Chapter 3: UK ESRD incident rates in 2008: National and centre-specific analyses. *Nephron. Clin. Pract.* 2010, 115, c9–c39.

5. Collins, A.J.; Foley, R.N.; Chavers, B.; Gilbertson, D.; Herzog, C.; Johansen, K.; Kasiske, B.; Kutner, N.; Liu, J.; St Peter, W.; et al. United States renal data system 2011 annual data report: Atlas of chronic kidney disease & end-stage renal disease in the United States. *Am. J. Kidney Dis.* 2012, 59, e1–e420.

6. Collins, A.J.; Foley, R.N.; Herzog, C.; Chavers, B.; Gilbertson, D.; Ishani, A.; Kasiske, B.; Liu, J.; Mau, L.W.; McBean, M.; et al. US renal data system 2010 annual data report. *Am. J. Kidney Dis.* 2011, 57, e1–e526.

7. Parving, H.H.; Oxenboll, B.; Svendsen, P.A.; Christiansen, J.S.; Andersen, A.R. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. *Acta Endocrinol.* 1982, 100, 550–555.

8. Viberti, G.C.; Hill, R.D.; Jarrett, R.J.; Argyropoulos, A.; Mahmud, U.; Keen, H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. *Lancet* 1982, 1, 1430–1432.

9. Mogensen, C.E.; Christensen, C.K. Predicting diabetic nephropathy in insulin-dependent patients. *N. Engl. J. Med.* 1984, 311, 89–93.

10. Stephenson, J.; Fuller, J.H. Microvascular and acute complications in IDDM patients: The EURODIAB IDDM complications study. *Diabetologia* 1994, 37, 278–285.

11. Krolewski, A.S.; Warram, J.H.; Christlieb, A.R.; Busick, E.J.; Kahn, C.R. The changing natural history of nephropathy in type 1 diabetes. *Am. J. Med.* 1985, 78, 785–794.

12. Bojestig, M.; Arqvist, H.J.; Hermansson, G.; Karlberg, B.E.; Ludvigsson, J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. *N. Engl. J. Med.* 1994, 330, 15–18.

13. Forsblom, C.M.; Groop, P.H.; Ekstrand, A.; Groop, L.C. Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. *BMJ* 1992, 305, 1051–1053.

14. Steinke, J.M.; Sinaiko, A.R.; Kramer, M.S.; Sussa, S.; Chavers, B.M.; Mauer, M. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. *Diabetes* 2005, 54, 2164–2171.

15. Perkins, B.A.; Ficociello, L.H.; Silva, K.H.; Finkelstein, D.M.; Warram, J.H.; Krolewski, A.S. Regression of microalbuminuria in type 1 diabetes. *N. Engl. J. Med.* 2003, 348, 2285–2293.

16. Hovind, P.; Tarnow, L.; Rossing, P.; Jensen, B.R.; Graae, M.; Torp, I.; Binder, C.; Parving, H.H. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: Inception cohort study. *BMJ* 2004, 328, 1105.
17. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998, 317, 703–713.
18. Spinas, G.A. Blood glucose monitoring and late complications of diabetes—Consequences of the Diabetes Control and Complications Trial (DCCT). *Schweiz Med. Wochenschr.* 1993, 123, 2387–2389.
19. Chrisholm, D.J. The Diabetes Control and Complications Trial (DCCT). A milestone in diabetes management. *Med. J. Aust.* 1993, 159, 721–723.
20. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.; Shahinfar, S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N. Engl. J. Med.* 2001, 345, 861–869.
21. Rosolowsky, E.T.; Skupien, J.; Smiles, A.M.; Niewczas, M.; Roshan, B.; Stanton, R.; Eckfeldt, J.H.; Warram, J.H.; Krolewski, A.S. Risk for ESRD in type 1 diabetes remains high despite renoprotection. *J. Am. Soc. Nephrol.* 2011, 22, 545–553.
22. Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. *Diabetes* 2005, 54, 1615–1625.
23. Marrero, M.B.; Fulton, D.; Stepp, D.; Stern, D.M. Angiotensin II-induced signaling pathways in diabetes. *Curr. Diabetes Rev.* 2005, 1, 197–202.
24. Sharma, K.; Ziyadeh, F.N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. *Diabetes* 1995, 44, 1139–1146.
25. Natarajan, R.; Cai, Q. Monocyte retention in the pathology of atherosclerosis. *Future Cardiol.* 2005, 1, 331–340.
26. Yan, S.F.; Ramasamy, R.; Schmidt, A.M. Mechanisms of disease: Advanced glycation end-products and their receptor in inflammation and diabetes complications. *Nat. Clin. Pract. Endocrinol. Metab.* 2008, 4, 285–293.
27. Mcmahon, B.; Mitchell, D.; Shattock, R.; Martin, F.; Brady, H.R.; Godson, C. Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. *FASEB J.* 2002, 16, 1817–1819.
28. Borgeson, E.; Godson, C. Molecular circuits of resolution in renal disease. *Sci. World J.* 2010, 10, 1370–1385.
29. King, G.L. The role of inflammatory cytokines in diabetes and its complications. *J. Periodontol.* 2008, 79, 1527–1534.
30. Geraldes, P.; King, G.L. Activation of protein kinase C isoforms and its impact on diabetic complications. *Circ. Res.* 2010, 106, 1319–1331.
31. Schmidt, A.M.; Yan, S.D.; Wautier, J.L.; Stern, D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. *Circ. Res.* 1999, 84, 489–497.
32. Schmid, H.; Boucherot, A.; Yasuda, Y.; Henger, A.; Brunner, B.; Eichinger, F.; Nitsche, A.; Kiss, E.; Bleich, M.; Grone, H.J.; *et al.* Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. *Diabetes* 2006, 55, 2993–3003.
33. Villeneuve, L.M.; Natarajan, R. The role of epigenetics in the pathology of diabetic complications. *Am. J. Physiol. Ren. Physiol.* 2010, 299, F14–F25.
34. Pezzolesi, M.G.; Poznik, G.D.; Mychaleckyj, J.C.; Paterson, A.D.; Barati, M.T.; Klein, J.B.; Ng, D.P.; Placha, G.; Canani, L.H.; Bochenski, J.; et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. *Diabetes* **2009**, *58*, 1403–1410.

35. Sandholm, N.; Salem, R.M.; McKnight, A.J.; Brennan, E.P.; Forsblom, C.; Isakova, T.; McKay, G.J.; Williams, W.W.; Sadlier, D.M.; Makinen, V.P.; et al. New susceptibility loci associated with kidney disease in type 1 diabetes. *PLoS Genet.* **2012**, *8*, e1002921.

36. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N. Engl. J. Med.* **1993**, *329*, 977–986.

37. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* **1998**, *352*, 837–853.

38. Clarkson, M.R.; Murphy, M.; Gupta, S.; Lambe, T.; Mackenzie, H.S.; Godson, C.; Martin, F.; Brady, H.R. High glucose-altered gene expression in mesangial cells. Actin-regulatory protein gene expression is triggered by oxidative stress and cytoskeletal disassembly. *J. Biol. Chem.* **2002**, *277*, 9707–9712.

39. Murphy, M.; Godson, C.; Cannon, S.; Kato, S.; Mackenzie, H.S.; Martin, F.; Brady, H.R. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. *J. Biol. Chem.* **1999**, *274*, 5830–5834.

40. McKnight, A.J.; Patterson, C.C.; Pettigrew, K.A.; Savage, D.A.; Kilner, J.; Murphy, M.; Sadlier, D.; Maxwell, A.P. A GREM1 gene variant associates with diabetic nephropathy. *J. Am. Soc. Nephrol.* **2010**, *21*, 773–781.

41. McMahon, R.; Murphy, M.; Clarkson, M.; Taal, M.; Mackenzie, H.S.; Godson, C.; Martin, F.; Brady, H.R. IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-beta1. *J. Biol. Chem.* **2000**, *275*, 9901–9904.

42. Murphy, M.; Docherty, N.G.; Griffin, B.; Howlin, J.; McARDLE, E.; McMahon, R.; Schmidt, H.; Kretzler, M.; Droguett, A.; Mezzano, S.; et al. IHG-1 amplifies TGF-beta1 signaling and is increased in renal fibrosis. *J. Am. Soc. Nephrol.* **2008**, *19*, 1672–1680.

43. Krupa, A.; Jenkins, R.; Luo, D.D.; Lewis, A.; Phillips, A.; Fraser, D. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. *J. Am. Soc. Nephrol.* **2010**, *21*, 438–447.

44. Dey, N.; Das, F.; Mariappan, M.M.; Mandal, C.C.; Ghosh-Choudhury, N.; Kasinath, B.S.; Choudhury, G.G. MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. *J. Biol. Chem.* **2011**, *286*, 25586–25603.

45. Wang, Q.; Wang, Y.; Minto, A.W.; Wang, J.; Shi, Q.; Li, X.; Quigg, R.J. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. *FASEB J.* **2008**, *22*, 4126–4135.

46. Sun, G.; Reddy, M.A.; Yuan, H.; Lanting, L.; Kato, M.; Natarajan, R. Epigenetic histone methylation modulates fibrotic gene expression. *J. Am. Soc. Nephrol.* **2010**, *21*, 2069–2080.
47. Gao, C.; Chen, G.; Liu, L.; Li, X.; He, J.; Jiang, L.; Zhu, J.; Xu, Y. Impact of high glucose and proteasome inhibitor MG132 on Histone H2A and H2B ubiquitination in rat glomerular mesangial cells. *J. Diabetes Res.* 2013, 2013, 589474.

48. Shi, Y.; Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* 2003, 113, 685–700.

49. Schmierer, B.; Hill, C.S. TGFbeta-SMAD signal transduction: Molecular specificity and functional flexibility. *Nat. Rev. Mol. Cell Biol.* 2007, 8, 970–982.

50. Chaudhury, A.; Howe, P.H. The tale of transforming growth factor-beta (TGFbeta) signaling: A soigne enigma. *IUBMB Life* 2009, 61, 929–939.

51. Reeves, W.B.; Andreoli, T.E. Transforming growth factor beta contributes to progressive diabetic nephropathy. *Proc. Natl. Acad. Sci. USA* 2000, 97, 7667–7669.

52. Russo, L.M.; del Re, E.; Brown, D.; Lin, H.Y. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: Amelioration by soluble TGF-beta type II receptor. *Diabetes* 2007, 56, 380–388.

53. Sharma, K.; Jin, Y.; Guo, J.; Ziyadeh, F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. *Diabetes* 1996, 45, 522–530.

54. Ziyadeh, F.N.; Hoffman, B.B.; Han, D.C.; Iglesias-De La Cruz, M.C.; Hong, S.W.; Isono, M.; Chen, S.; McGowan, T.A.; Sharma, K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. *Proc. Natl. Acad. Sci. USA* 2000, 97, 8015–8020.

55. Houlihan, C.A.; Akdeniz, A.; Tsalamandris, C.; Cooper, M.E.; Jerums, G.; Gilbert, R.E. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: Effects of angiotensin receptor blockade and sodium restriction. *Diabetes Care* 2002, 25, 1072–1077.

56. Goumenos, D.S.; Tsakas, S.; El Nahas, A.M.; Alexandri, S.; Oldroyd, S.; Kalliakmani, P.; Vlachojannis, J.G. Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria. *Nephrol. Dial. Transplant.* 2002, 17, 2145–2152.

57. Brennan, E.P.; Morine, M.J.; Walsh, D.W.; Roxburgh, S.A.; Lindenmeyer, M.T.; Brazil, D.P.; Gaora, P.O.; Roche, H.M.; Sadlier, D.M.; Cohen, C.D.; *et al.* Next-generation sequencing identifies TGF-beta1-associated gene expression profiles in renal epithelial cells reiterated in human diabetic nephropathy. *Biochim. Biophys. Acta* 2012, 1822, 589–599.

58. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. *J. Clin. Invest.* 2009, 119, 1420–1428.

59. LeBleu, V.S.; Taduri, G.; O’Connell, J.; Teng, Y.; Cooke, V.G.; Woda, C.; Sugimoto, H.; Kalluri, R. Origin and function of myofibroblasts in kidney fibrosis. *Nat. Med.* 2013, 19, 1047–1053.

60. Borges, F.T.; Melo, S.A.; Ozdemir, B.C.; Kato, N.; Revuelta, I.; Miller, C.A.; Gattone, V.H., 2nd; LeBleu, V.S.; Kalluri, R. TGF-beta1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. *J. Am. Soc. Nephrol.* 2013, 24, 385–392.
61. Yoshikawa, M.; Hishikawa, K.; Marumo, T.; Fujita, T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. *J. Am. Soc. Nephrol.* 2007, 18, 58–65.

62. Kato, M.; Putta, S.; Wang, M.; Yuan, H.; Lanting, L.; Nair, I.; Gunn, A.; Nakagawa, Y.; Shimano, H.; Todorov, I.; *et al.* TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. *Nat. Cell Biol.* 2009, 11, 881–889.

63. Kato, M.; Zhang, J.; Wang, M.; Lanting, L.; Yuan, H.; Rossi, J.J.; Natarajan, R. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. *Proc. Natl. Acad. Sci. USA* 2007, 104, 3432–3437.

64. Wang, B.; Herman-Edelstein, M.; Koh, P.; Burns, W.; Jandeleit-Dahm, K.; Watson, A.; Saleem, M.; Goodall, G.J.; Twigg, S.M.; Cooper, M.E.; *et al.* E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. *Diabetes* 2010, 59, 1794–1802.

65. Brennan, E.P.; Nolan, K.A.; Borgeson, E.; Gough, O.S.; McEvoy, C.M.; Docherty, N.G.; Higgins, D.F.; Murphy, M.; Sadlier, D.M.; Ali-Shah, S.T.; *et al.* Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFbetaR1. *J. Am. Soc. Nephrol.* 2013, 24, 627–637.

66. Gruden, G.; Thomas, S.; Burt, D.; Lane, S.; Chusney, G.; Sacks, S.; Viberti, G. Mechanical stretch induces vascular permeability factor in human mesangial cells: Mechanisms of signal transduction. *Proc. Natl. Acad. Sci. USA* 1997, 94, 12112–12116.

67. Crean, J.K.; Furlong, F.; Finlay, D.; Mitchell, D.; Murphy, M.; Conway, B.; Brady, H.R.; Godson, C.; Martin, F. Connective tissue growth factor [CTGF]/CCN2 stimulates mesangial cell migration through integrated dissolution of focal adhesion complexes and activation of cell polarization. *FASEB J.* 2004, 18, 1541–1543.

68. Faherty, N.; Curran, S.P.; O’Donovan, H.; Martin, F.; Godson, C.; Brazil, D.P.; Crean, J.K. CCN2/CTGF increases expression of miR-302 microRNAs, which target the TGFbeta type II receptor with implications for nephropathic cell phenotypes. *J. Cell Sci.* 2012, 125, 5621–5629.

69. Martinez-Estrada, O.M.; Letticke, L.A.; Essafi, A.; Guadix, J.A.; Slight, J.; Velecela, V.; Hall, E.; Reichmann, J.; Devenney, P.S.; Hohenstein, P.; *et al.* Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. *Nat. Genet.* 2010, 42, 89–93.

70. Breyer, M.D.; Bottinger, E.; Brosius, F.C., 3rd; Coffman, T.M.; Harris, R.C.; Heilig, C.W.; Sharma, K. Mouse models of diabetic nephropathy. *J. Am. Soc. Nephrol.* 2005, 16, 27–45.

71. Alpers, C.E.; Hudkins, K.L. Mouse models of diabetic nephropathy. *Curr. Opin. Nephrol. Hypertens.* 2011, 20, 278–284.

72. Brosius, F.C., 3rd; Alpers, C.E.; Bottinger, E.P.; Breyer, M.D.; Coffman, T.M.; Gurley, S.B.; Harris, R.C.; Kakoki, M.; Kretzler, M.; Leiter, E.H.; *et al.* Mouse models of diabetic nephropathy. *J. Am. Soc. Nephrol.* 2009, 20, 2503–2512.

73. Tesch, G.H.; Lim, A.K. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. *Am. J. Physiol. Ren. Physiol.* 2011, 300, F301–F310.

74. Higgins, D.F.; Kimura, K.; Bernhardt, W.M.; Shrimanker, N.; Akai, Y.; Hohenstein, B.; Saito, Y.; Johnson, R.S.; Kretzler, M.; Cohen, C.D.; *et al.* Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. *J. Clin. Invest.* 2007, 117, 3810–3820.
75. Chevalier, R.L. Specific molecular targeting of renal injury in obstructive nephropathy. *Kidney Int. 2006*, 70, 1200–1201.

76. Chevalier, R.L. Obstructive nephropathy: Towards biomarker discovery and gene therapy. *Nat. Clin. Pract. Nephrol. 2006*, 2, 157–168.

77. Chevalier, R.L. Pathogenesis of renal injury in obstructive uropathy. *Curr. Opin. Pediatr. 2006*, 18, 153–160.

78. Hong, S.W.; Isono, M.; Chen, S.; Iglesias-De La Cruz, M.C.; Han, D.C.; Ziyadeh, F.N. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. *Am. J. Pathol. 2001*, 158, 1653–1663.

79. Usui, H.; Shikata, K.; Matsuda, M.; Okada, S.; Ogawa, D.; Yamashita, T.; Hida, K.; Satoh, M.; Wada, J.; Makino, H. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. *Nephrol. Dial. Transplant. 2003*, 18, 265–272.

80. Zhang, Q.; Xiao, X.; Li, M.; Li, W.; Yu, M.; Zhang, H.; Sun, X.; Mao, L.; Xiang, H. Gene expression profiling in glomeruli of diabetic nephropathy rat. *Exp. Biol. Med. 2012*, 237, 903–911.

81. Wada, J.; Zhang, H.; Tsuchiyama, Y.; Hiragushi, K.; Hida, K.; Shikata, K.; Kanwar, Y.S.; Makino, H. Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis. *Kidney Int. 2001*, 59, 1363–1373.

82. Woroniecka, K.I.; Park, A.S.; Mohtat, D.; Thomas, D.B.; Pullman, J.M.; Susztak, K. Transcriptome analysis of human diabetic kidney disease. *Diabetes 2011*, 60, 2354–2369.

83. Reich, H.N.; Tritchler, D.; Cattran, D.C.; Herzenberg, A.M.; Eichinger, F.; Boucherot, A.; Henger, A.; Berthier, C.C.; Nair, V.; Cohen, C.D.; et al. A molecular signature of proteinuria in glomerulonephritis. *PLoS One 2010*, 5, e13451.

84. Tonna, S.; El-Osta, A.; Cooper, M.E.; Tikellis, C. Metabolic memory and diabetic nephropathy: Potential role for epigenetic mechanisms. *Nat. Rev. Nephrol. 2010*, 6, 332–341.

85. El-Osta, A.; Brasacchio, D.; Yao, D.; Pocai, A.; Jones, P.L.; Roeder, R.G.; Cooper, M.E.; Brownlee, M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. *J. Exp. Med. 2008*, 205, 2409–2417.

86. Miao, F.; Wu, X.; Zhang, L.; Yuan, Y.C.; Riggs, A.D.; Natarajan, R. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. *J. Biol. Chem. 2007*, 282, 13854–13863.

87. Bell, C.G.; Teschendorff, A.E.; Rakyan, V.K.; Maxwell, A.P.; Beck, S.; Savage, D.A. Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. *BMC Med. Genomics 2010*, 3, 33.

88. Brennan, E.P.; Ehrich, M.; Brazil, D.P.; Crean, J.K.; Murphy, M.; Sadlier, D.M.; Martin, F.; Godson, C.; McKnight, A.J.; van den Boom, D.; et al. Comparative analysis of DNA methylation profiles in peripheral blood leukocytes versus lymphoblastoid cell lines. *Epigenetics 2009*, 4, 159–164.

89. Bechtel, W.; McGoohan, S.; Zeisberg, E.M.; Muller, G.A.; Kalbacher, H.; Salant, D.J.; Muller, C.A.; Kalluri, R.; Zeisberg, M. Methylation determines fibroblast activation and fibrogenesis in the kidney. *Nat. Med. 2010*, 16, 544–550.
90. Brennan, E.P. Lipoxins attenuate renal fibrosis by induction of let-7c and suppression of TGFβR1. *J. Am. Soc. Nephrol.* 2013, in press.

91. Zhong, X.; Chung, A.C.; Chen, H.Y.; Meng, X.M.; Lan, H.Y. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. *J. Am. Soc. Nephrol.* 2011, 22, 1668–1681.

92. Wang, B.; Komers, R.; Carew, R.; Winbanks, C.E.; Xu, B.; Herman-Edelstein, M.; Koh, P.; Thomas, M.; Jandeleit-Dahm, K.; Gregorevic, P.; et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. *J. Am. Soc. Nephrol.* 2012, 23, 252–265.

93. Chung, A.C.; Huang, X.R.; Meng, X.; Lan, H.Y. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. *J. Am. Soc. Nephrol.* 2010, 21, 1317–1325.

94. Argyropoulos, C.; Wang, K.; McClarty, S.; Huang, D.; Bernardo, J.; Ellis, D.; Orchard, T.; Galas, D.; Johnson, J. Urinary microRNA profiling in the nephropathy of type 1 diabetes. *PLoS One* 2013, 8, e54662.

95. Beltrami, C.; Clayton, A.; Phillips, A.O.; Fraser, D.J.; Bowen, T. Analysis of urinary microRNAs in chronic kidney disease. *Biochem. Soc. Trans.* 2012, 40, 875–879.

96. Bouchie, A. First microRNA mimic enters clinic. *Nat. Biotechnol.* 2013, 31, 577.

97. Borch-Johnsen, K.; Norgaard, K.; Hommel, E.; Mathiesen, E.R.; Jensen, J.S.; Deckert, T.; Parving, H.H. Is diabetic nephropathy an inherited complication? *Kidney Int.* 1992, 41, 719–722.

98. Quinn, M.; Angelico, M.C.; Warram, J.H.; Krolewski, A.S. Familial factors determine the development of diabetic nephropathy in patients with IDDM. *Diabetologia* 1996, 39, 940–945.

99. Seaquist, E.R.; Goetz, F.C.; Rich, S.; Barbosa, J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. *N. Engl. J. Med.* 1989, 320, 1161–1165.

100. Barzilay, J.; Warram, J.H.; Bak, M.; Laffel, L.M.; Canessa, M.; Krolewski, A.S. Predisposition to hypertension: Risk factor for nephropathy and hypertension in IDDM. *Kidney Int.* 1992, 41, 723–730.

101. Earle, K.; Walker, J.; Hill, C.; Viberti, G. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. *N. Engl. J. Med.* 1992, 326, 673–677.

102. Moczulski, D.K.; Rogus, J.J.; Antonellis, A.; Warram, J.H.; Krolewski, A.S. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: Results of novel discordant sib-pair analysis. *Diabetes* 1998, 47, 1164–1169.

103. Chistiakov, D.A.; Savost’anov, K.V.; Shestakova, M.V.; Chugunova, L.A.; Samkhalova, M.; Dedov, I.I.; Nosikov, V.V. Confirmation of a susceptibility locus for diabetic nephropathy on chromosome 3q23-q24 by association study in Russian type 1 diabetic patients. *Diabetes Res. Clin. Pract.* 2004, 66, 79–86.

104. Osterholm, A.M.; He, B.; Pitkaniemi, J.; Albinsson, L.; Berg, T.; Sarti, C.; Tuomilehto, J.; Tryggvason, K. Genome-wide scan for type 1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a single locus on chromosome 3q. *Kidney Int.* 2007, 71, 140–145.

105. Imperatore, G.; Hanson, R.L.; Pettitt, D.J.; Kobes, S.; Bennett, P.H.; Knowler, W.C. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. *Pima Diabetes Genes Group. Diabetes* 1998, 47, 821–830.
106. Bowden, D.W.; Colicigno, C.J.; Langefeld, C.D.; Sale, M.M.; Williams, A.; Anderson, P.J.; Rich, S.S.; Freedman, B.I. A genome scan for diabetic nephropathy in African Americans. *Kidney Int. 2004*, 66, 1517–1526.

107. Krolewski, A.S.; Poznik, G.D.; Placha, G.; Canani, L.; Dunn, J.; Walker, W.; Smiles, A.; Krolewski, B.; Fogarty, D.G.; Moczulski, D.; *et al*. A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. *Kidney Int. 2006*, 69, 129–136.

108. Iyengar, S.K.; Abboud, H.E.; Goddard, K.A.; Saad, M.F.; Adler, S.G.; Arar, N.H.; Bowden, D.W.; Duggirala, R.; Elston, R.C.; Hanson, R.L.; *et al*. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: The family investigation of nephropathy and diabetes (FIND). *Diabetes 2007*, 56, 1577–1585.

109. Vardarli, I.; Baier, L.J.; Hanson, R.L.; Akkoyun, I.; Fischer, C.; Rohmeiss, P.; Basci, A.; Bartram, C.R.; van der Woude, F.J.; Janssen, B. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3–23. *Kidney Int. 2002*, 62, 2176–2183.

110. Schelling, J.R.; Abboud, H.E.; Nicholas, S.B.; Pahl, M.V.; Sedor, J.R.; Adler, S.G.; Arar, N.H.; Bowden, D.W.; Elston, R.C.; Freedman, B.I.; *et al*. Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: The Family Investigation of Nephropathy and Diabetes (FIND). *Diabetes 2008*, 57, 235–243.

111. McKnight, A.J.; Savage, D.A.; Patterson, C.C.; Brady, H.R.; Maxwell, A.P. Resequencing of the characterised CTGF gene to identify novel or known variants, and analysis of their association with diabetic nephropathy. *J. Hum. Genet. 2006*, 51, 383–386.

112. Pociot, F.; Hansen, P.M.; Karlsen, A.E.; Langdahl, B.L.; Johannesen, J.; Nerup, J. TGF-beta1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy. *J. Am. Soc. Nephrol. 1998*, 9, 2302–2307.

113. Patel, A.; Scott, W.R.; Lympany, P.A.; Rippin, J.D.; Gill, G.V.; Barnett, A.H.; Bain, S.C. The TGF-beta1 gene codon 10 polymorphism contributes to the genetic predisposition to nephropathy in Type 1 diabetes. *Diabet. Med. 2005*, 22, 69–73.

114. Ewens, K.G.; George, R.A.; Sharma, K.; Ziyadeh, F.N.; Spielman, R.S. Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. *Diabetes 2005*, 54, 3305–3318.

115. McKnight, A.J.; Maxwell, A.P.; Patterson, C.C.; Brady, H.R.; Savage, D.A. Association of VEGF-1499C-->T polymorphism with diabetic nephropathy in type 1 diabetes mellitus. *J. Diabetes Complicat. 2007*, 21, 242–245.

116. McKnight, A.J.; Pettigrew, K.A.; Patterson, C.C.; Kilner, J.; Sadlier, D.M.; Maxwell, A.P. Investigation of the association of BMP gene variants with nephropathy in Type 1 diabetes mellitus. *Diabet. Med. 2010*, 27, 624–630.

117. Ma, J.; Mollsten, A.; Prazny, M.; Falhammar, H.; Brismar, K.; Dahlquist, G.; Efendic, S.; Gu, H.F. Genetic influences of the intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in development of Type 1 diabetes and diabetic nephropathy. *Diabet. Med. 2006*, 23, 1093–1099.

118. Yang, B.; Houlberg, K.; Millward, A.; Demaine, A. Polymorphisms of chemokine and chemokine receptor genes in Type 1 diabetes mellitus and its complications. *Cytokine 2004*, 26, 114–121.
119. Poirier, O.; Nicaud, V.; Vionnet, N.; Raoux, S.; Tarnow, L.; Vlassara, H.; Parving, H.H.; Cambien, F. Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes 2001, 50, 1214–1218.

120. McKay, G.J.; Savage, D.A.; Patterson, C.C.; Lewis, G.; McKnight, A.J.; Maxwell, A.P. Association analysis of dyslipidemia-related genes in diabetic nephropathy. PLoS One 2013, 8, e58472.

121. Doria, A.; Warram, J.H.; Krolewski, A.S. Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 1994, 43, 690–695.

122. Marre, M.; Bernadet, P.; Gallois, Y.; Savagner, F.; Guyene, T.T.; Hallab, M.; Cambien, F.; Passa, P.; Alhenc-Gelas, F. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994, 43, 384–388.

123. Tarnow, L.; Cambien, F.; Rossing, P.; Nielsen, F.S.; Hansen, B.V.; Lecerf, L.; Poirier, O.; Danilov, S.; Parving, H.H. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995, 44, 489–494.

124. Chowdhury, T.A.; Dronsfield, M.J.; Kumar, S.; Gough, S.L.; Gibson, S.P.; Khatoon, A.; MacDonald, F.; Rowe, B.R.; Dunger, D.B.; Dean, J.D.; et al. Examination of two genetic polymorphisms within the renin-angiotensin system: No evidence for an association with nephropathy in IDDM. Diabetologia 1996, 39, 1108–1114.

125. Boright, A.P.; Paterson, A.D.; Mirea, L.; Bull, S.B.; Mowjoodi, A.; Scherer, S.W.; Zinman, B. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: The DCCT/EDIC Genetics Study. Diabetes 2005, 54, 1238–1244.

126. Hadjadj, S.; Tarnow, L.; Forsblom, C.; Kazeem, G.; Marre, M.; Groop, P.H.; Parving, H.H.; Cambien, F.; Tregouet, D.A.; Gut, I.G.; et al. Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: Case-control, haplotype, and family-based study in three European populations. J. Am. Soc. Nephrol. 2007, 18, 1284–1291.

127. Ng, D.P.; Tai, B.C.; Koh, D.; Tan, K.W.; Chia, K.S. Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: A meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 2005, 48, 1008–1016.

128. Osawa, N.; Koya, D.; Araki, S.; Uzu, T.; Tsunoda, T.; Kashiwagi, A.; Nakamura, Y.; Maeda, S. Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy. J. Hum. Genet. 2007, 52, 143–151.

129. Barrett, J.C.; Clayton, D.G.; Concannon, P.; Akolkar, B.; Cooper, J.D.; Erlich, H.A.; Julier, C.; Morahan, G.; Nerup, J.; Nierras, C.; et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 2009, 41, 703–707.

130. Zeggini, E.; Scott, L.J.; Saxena, R.; Voight, B.F.; Marchini, J.L.; Hu, T.; de Bakker, P.I.; Abecasis, G.R.; Almgren, P.; Andersen, G.; et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 2008, 40, 638–645.
131. Voight, B.F.; Scott, L.J.; Steinthorsdottir, V.; Morris, A.P.; Dina, C.; Welch, R.P.; Zeggini, E.; Huth, C.; Aulchenko, Y.S.; Thorleifsson, G.; et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat. Genet.* 2010, 42, 579–589.

132. Dupuis, J.; Langenberg, C.; Prokopenko, I.; Saxena, R.; Soranzo, N.; Jackson, A.U.; Wheeler, E.; Glazer, N.L.; Bouatia-Naji, N.; Gloyn, A.L.; et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat. Genet.* 2010, 42, 105–116.

133. Sladek, R.; Rocheleau, G.; Rung, J.; Dina, C.; Shen, L.; Serre, D.; Boutin, P.; Vincent, D.; Belisle, A.; Hadjadj, S.; et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature* 2007, 445, 881–885.

134. Bell, J.T.; Timpson, N.J.; Rayner, N.W.; Zeggini, E.; Frayling, T.M.; Hattersley, A.T.; Morris, A.P.; McCarthy, M.I. Genome-wide association scan allowing for epistasis in type 2 diabetes. *Ann. Hum. Genet.* 2011, 75, 10–19.

135. Kao, W.H.; Klag, M.J.; Meoni, L.A.; Reich, D.; Berthier-Schaad, Y.; Li, M.; Coresh, J.; Patterson, N.; Tandon, A.; Powe, N.R.; et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. *Nat. Genet.* 2008, 40, 1185–1192.

136. Kopp, J.B.; Smith, M.W.; Nelson, G.W.; Johnson, R.C.; Freedman, B.I.; Bowden, D.W.; Oleksyk, T.; McKenzie, L.M.; Kajiyama, H.; Ahuja, T.S.; et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. *Nat. Genet.* 2008, 40, 1175–1184.

137. Stanescu, H.C.; Arcos-Burgos, M.; Medlar, A.; Bockenhauer, D.; Kottgen, A.; Dragomirescu, L.; Voinescu, C.; Patel, N.; Pearce, K.; Hubank, M.; et al. Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy. *N. Engl. J. Med.* 2011, 364, 616–626.

138. Gharavi, A.G.; Yan, Y.; Scolari, F.; Schena, F.P.; Frasca, G.M.; Ghiggeri, G.M.; Cooper, K.; Amoroso, A.; Viola, B.F.; Battini, G.; et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22–23. *Nat. Genet.* 2000, 26, 354–357.

139. Lyons, P.A.; Rayner, T.F.; Trivedi, S.; Holle, J.U.; Watts, R.A.; Jayne, D.R.; Baslund, B.; Brenchley, P.; Chaudhry, A.N.; et al. Genetically distinct subsets within ANCA-associated vasculitis. *N. Engl. J. Med.* 2012, 367, 214–223.

140. Palmer, N.D.; Freedman, B.I. Diabetic nephropathy: FRMD3 in diabetic nephropathy—guilt by association. *Nat. Rev. Nephrol.* 2013, 9, 313–314.

141. Martini, S.; Nair, V.; Patel, S.R.; Eichinger, F.; Nelson, R.G.; Weil, E.J.; Pezzolesi, M.G.; Krolewski, A.S.; Randolph, A.; Keller, B.J.; et al. From single nucleotide polymorphism to transcriptional mechanism: A model for FRMD3 in diabetic nephropathy. *Diabetes* 2013, 62, 2605–2612.

142. Mooyaart, A.L.; Valk, E.J.; van Es, L.A.; Bruijn, J.A.; de Heer, E.; Freedman, B.I.; Dekkers, O.M.; Baelde, H.J. Genetic associations in diabetic nephropathy: A meta-analysis. *Diabetologia* 2011, 54, 544–553.

143. Wallace, C.; Rotival, M.; Cooper, J.D.; Rice, C.M.; Yang, J.H.; McNeill, M.; Smyth, D.J.; Niblett, D.; Cambien, F.; Tiret, L.; et al. Statistical colocalization of monocyte gene expression and genetic risk variants for type 1 diabetes. *Hum. Mol. Genet.* 2012, 21, 2815–2824.

144. Zeng, F.; Zhang, M.Z.; Singh, A.B.; Zent, R.; Harris, R.C. ErbB4 isoforms selectively regulate growth factor induced Madin-Darby canine kidney cell tubulogenesis. *Mol. Biol. Cell* 2007, 18, 4446–4456.
145. Veikkolainen, V.; Naillat, F.; Railo, A.; Chi, L.; Manninen, A.; Hohenstein, P.; Hastie, N.; Vainio, S.; Elenius, K. ErbB4 modulates tubular cell polarity and lumen diameter during kidney development. *J. Am. Soc. Nephrol.* **2012**, *23*, 112–122.

146. Sandholm, N.; McKnight, A.J.; Salem, R.M.; Brennan, E.P.; Forsblom, C.; Harjutsalo, V.; Makinen, V.P.; McKay, G.J.; Sadlier, D.M.; Williams, W.W.; et al. Chromosome 2q31.1 Associates with ESRD in Women with Type 1 Diabetes. *J. Am. Soc. Nephrol.* **2013**, *24*, 1537–1543.

147. Williams, W.W.; Salem, R.M.; McKnight, A.J.; Sandholm, N.; Forsblom, C.; Taylor, A.; Guiducci, C.; McAteer, J.B.; McKay, G.J.; Isakova, T.; et al. Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy. *Diabetes* **2012**, *61*, 2187–2194.

148. SUrroate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools. Available online: www.imi-summit.eu/ (accessed on 31 October 2013).

149. Nephromine. Available online: www.nephromine.org/ (accessed on 31 October 2013).

150. The Kidney & Urinary Pathway Knowledge Base. Available online: www.kupkb.org/ (accessed on 31 October 2013).

151. Jupp, S.; Klein, J.; Schanstra, J.; Stevens, R. Developing a kidney and urinary pathway knowledge base. *J. Biomed. Semant.* **2011**, *2*, S7.

152. Human Kidney and Urine Proteome Project. Available online: www.hkupp.org/ (accessed on 31 October 2013).

153. European Renal Genome Project. Available online: www.euregene.org/ (accessed on 31 October 2013).

154. Fechete, R.; Heinzel, A.; Perco, P.; Monks, K.; Sollner, J.; Stelzer, G.; Eder, S.; Lancet, D.; Oberbauer, R.; Mayer, G.; et al. Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. *Proteomics Clin. Appl.* **2011**, *5*, 354–366.

155. Tranchevent, L.C.; Barriot, R.; Yu, S.; van Vooren, S.; van Loo, P.; Coessens, B.; de Moor, B.; Aerts, S.; Moreau, Y. ENDEAVOUR update: A web resource for gene prioritization in multiple species. *Nucleic Acids Res.* **2008**, *36*, W377–W384.

156. Su, A.I.; Wiltshire, T.; Batalov, S.; Lapp, H.; Ching, K.A.; Block, D.; Zhang, J.; Soden, R.; Hayakawa, M.; Kreiman, G.; et al. A gene atlas of the mouse and human protein-encoding transcriptomes. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 6062–6067.

157. Pers, T.H.; Hansen, N.T.; Lage, K.; Koefoed, P.; Dworzynski, P.; Miller, M.L.; Flint, T.J.; Mellerup, E.; Dam, H.; Andreassen, O.A.; et al. Meta-analysis of heterogeneous data sources for genome-scale identification of risk genes in complex phenotypes. *Genet. Epidemiol.* **2011**, *35*, 318–332.

158. Pers, T.H.; Dworzynski, P.; Thomas, C.E.; Lage, K.; Brunak, S. MetaRanker 2.0: A web server for prioritization of genetic variation data. *Nucleic Acids Res.* **2013**, *41*, W104–W108.

159. Perkins, B.A.; Ficociello, L.H.; Roshan, B.; Warram, J.H.; Krolevski, A.S. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. *Kidney Int.* **2010**, *77*, 57–64.
160. Krolewski, A.S.; Niewczas, M.A.; Skupien, J.; Gohda, T.; Smiles, A.; Eckfeldt, J.H.; Doria, A.; Warram, J.H. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. *Diabetes Care* **2013**, [Epub ahead of print].

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).